BREAKING NEWS: HGS rejects GSK $2.60 billion takeover bid

Article Date: 19/04/2012 10:03
BREAKING NEWS: HGS rejects GSK $2.60 billion takeover bid

Vacancy Search

Quick job search

Advanced Search

Latest News

Amgen/AZ psoriasis drug impresses again in Phase III

Amgen/AZ psoriasis drug impresses again in Phase III

Final NICE stance on Lundbeck's Selincro, Novartis' Glivec

Final NICE stance on Lundbeck's Selincro, Novartis' Glivec

US Congress bid to penalise high-cost generics

US Congress bid to penalise high-cost generics

Europe approves J&J HIV combo Rezolsta

Europe approves J&J HIV combo Rezolsta

Cell Medica gets £50 million funding boost

Cell Medica gets £50 million funding boost

EU approves Lilly diabetes drug Trulicity

EU approves Lilly diabetes drug Trulicity

Migraine market set for fast growth, driven by two novel therapies

Migraine market set for fast growth, driven by two novel therapies

Lundbeck CEO falls on his sword over share gift

Lundbeck CEO falls on his sword over share gift

Interview – Oncology advances leave a niche for Helsinn

Cancer supportive care will not strike most biotech watchers as a hot area of innovation or investor returns, but Riccardo Braglia, chief executive of the private Swiss group Helsinn, seems...

AZ gets EU approval for COPD combo

AZ gets EU approval for COPD combo
more news